Table 3. Up-coming combination trials with third generation EGFR-TKIs.
| Eudract Number | No. of arms | Trial phase | No. of estimated patients | Inclusion of patients pre-treated with 3rd generation TKI | EGFR-TKI | Combined drug | Target of the combined drug |
|---|---|---|---|---|---|---|---|
| NCT02496663 | 1 | 1 | 30 | No | Osimertinib | Necitumumab | EGFR |
| NCT02503722 | 1 | 1 | 36 | Yes (in dose escalation phase) | Osimertinib | INK128 | TORC1/2 |
| NCT02520778 | 1 | 1 | 50 | Yes (in dose escalation phase) | Osimertinib | Navitoclax | Bcl2 family |
| NCT02335944 | 1 | 1b/2 | 80 | No | EGF816 | INC280 | MET |
| NCT02323126 | 2 | 2 | 100 | No | EGF816† | Nivolumab† | PD-1 |
| NCT02789345 | 2 | 1 | 74 | No | Osimertinib | Ramucirumab | VEGFR2 |
| Osimertinib | Necitumumab | EGFR | |||||
| NCT02143466 | 3 | 1b | 198 | Yes (depending on the specific cohort) | Osimertinib | Selumetinib | MEK |
| Osimertinib‡ | Durvalumab‡ | PD-L1 | |||||
| Osimertinib | AZD6094 | MET |
†, the other arm will test nivolumab plus INC280; ‡, arm closed due to toxicity. EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; PD-1, programmed cell death 1; VEGFR2, vascular endothelial growth factor receptor 2; PD-L1, programmed cell death 1 ligand 1.